EN DE
Watch Vycor Medical Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Vycor Medical Inc (VYCO) fair value: what the stock is really worth

As of Nov 3, 2026: fair value (intrinsic value) of Vycor Medical Inc stock $0.03, price $0.05, that is 40.0% below the price, quality 47 out of 100. Rating: strongly overvalued. Calculated from audited financials with 3 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

VM Vycor Medical Inc logo Thin data Nov 7, 2026

Vycor Medical Inc

VYCO · US
Very expensive, weak quality

Our calculation puts a fair price 40% below what the stock costs today.

Quality 47/100
Expensive Growth (revenue 5y +10.3 %/yr in USD)
Negative equity (buybacks among others)
Revenue last quarter 16% below a year ago.
Fair value $0.0300 · Strongly overvalued
Loss-making · -3.3% net margin (TTM)
Negative free cash flow
Trails peers (1/8)
Narrow moat 13/100 · thin data
Thin data
⚠ Thinly traded
Watch Vycor Medical Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$0.2800 $0.0260 Fair Value $0.0300 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.

How to read this chart

60‑month range $0.0260 – $0.2800 · the $0.0500 price screens above the $0.0300 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 7, 2026.

Follow Vycor Medical in your weekly email

Every Wednesday you see whether Vycor Medical is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Vycor Medical, Inc. designs, develops, and markets neurological medical devices and therapies in the United States and Europe. The company operates through two segments: Vycor Medical and NovaVision.

Show moreShow less

Its Vycor Medical segment provides devices for neurosurgery comprising ViewSite Brain Access System, a retraction and access system for brain and spine surgeries.

The NovaVision segment offers non-invasive computer-based rehabilitation therapies targeted at people who have impaired vision as a result of stroke or other brain injury. It has a license agreement with a German-based partner. It primarily serves hospitals and medical professionals.

The company was incorporated in 2005 and is headquartered in Boca Raton, Florida. Vycor Medical, Inc. operates as a subsidiary of Fountainhead Capital Management Ltd.

Stock analysis

Vycor Medical Inc (VYCO) currently trades at $0.0500, while our model-based Fair Value estimate is $0.0300, 40% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Economic Profit group reads highest at a median of $0.0100 per share, and 0 of the 3 models we run sit above the $0.0500 price.

Bear case: the Earnings-Based group reads lowest at $0.0100, and 3 of the 3 models stay below the price. Data coverage for this calculation is low.

Quality & growth

The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Vycor Medical Inc reported revenue of $1.9M in FY2025 versus $1.4M in FY2021, a compound +7.5%/yr. Reported net income was −$72.4K in FY2025.

Key figures

Market cap $1.7M Micro · P/S ratio 0.96 · Net margin −3.9% · Return on assets (EBIT) −15.0% (5-year average) · Operating margin 1.6% · Revenue (TTM) $1.8M · Revenue growth (YoY) −15.7% · Free cash flow −$18.7K.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 13 out of 100 (low confidence).

What moves the price

The share trades about 75% below its 52-week high and 92% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at −40%, VYCO screens richer than that median.

Fair Value models

Bear $0.0300 Fair Value $0.0300 Bull $0.0300
Price $0.0500 · Downside -40.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
EPV $0.0100 $0.0100 $0.0100 74
ROIC Compounder $0.0100 $0.0100 $0.0100 72
EV/EBITDA n/a $0.0100 $0.0200 57
All 3 models by family
Earnings-Based
EPV $0.0100 $0.0100 $0.0100 74
Multiples
EV/EBITDA n/a $0.0100 $0.0200 57
Economic Profit
ROIC Compounder $0.0100 $0.0100 $0.0100 72

Open the full fair value analysis →

Quality Score breakdown

Overall quality 47/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 50
How much profit the company makes from its sales and capital
Quality Growth 62
Are margins and returns getting better?
Cashflow 9
Do the profits arrive as real cash?
Financial strength 9
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 6
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 7
Distance to the 52-week high, does not count
New shares 77
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 36/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+17.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.3%
Start year 2020 (pandemic). Over 10 years: +5.0% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.4%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−63.2% (2020) → 1.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

VYCO screens overvalued: fair value 40% below the price. Compare with Abbott Laboratories, →

Compare Vycor Medical Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 319 stocks

Beats the industry median on 1/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 47 · Below median
Fair Value upside −40.0% · Below median
Profitability
Return on equity (12 months) Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets −8.7% · Below median
Net margin (12 months) −3.3% · Below median
Operating margin (12 months) 1.6% · Below median
Growth and dividend
Revenue growth (quarter YoY) −15.7% · Bottom 25%
Balance sheet
Debt / equity Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (12 months) 0.92× · Cheapest 25%
EV/EBITDA 15.6× · Pricier than median

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥181.10 ¥202.57 +12% vs VYCO
Stryker Corporation SYK $325.87 $358.46 +10% vs VYCO
Boston Scientific Corporation BSX $42.75 $47.03 +10% vs VYCO
DexCom, Inc DXCM $79.41 $87.35 +10% vs VYCO
GE HealthCare Technologies Inc GEHC $82.38 $69.92 −15% vs VYCO
Edwards Lifesciences Corporation EW $102.14 $81.94 −20% vs VYCO
Siemens Healthineers AG SHL €43.16 €34.51 −20% vs VYCO
Abbott Laboratories, ABT $109.93 $75.28 −32% vs VYCO
Medtronic plc MDT $101.80 $65.61 −36% vs VYCO
Koninklijke Philips N.V PHIA €27.30 €15.23 −44% vs VYCO

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Vycor Medical Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Vycor Medical Inc Fair Value". https://www.fairvalue-calculator.com/stock/VYCO

Frequently asked questions

Is Vycor Medical Inc (VYCO) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of $0.0300 versus the last price from Nov 3, 2026 of $0.0500, about 40% lower (overvalued).
What is the fair value of VYCO?
Our model-based fair value for Vycor Medical Inc is $0.0300 (as of Nov 7, 2026), built from audited fundamentals. Last price (from Nov 3, 2026): $0.0500.
What is the quality score of VYCO?
Vycor Medical Inc has a Quality Score of 47/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Vycor Medical Inc (VYCO)?
Our model-based price target is the fair value of $0.0300 (as of Nov 7, 2026) from 3 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the Vycor Medical Inc stock forecast for 2026?
Our models put fair value at $0.0300, about 40% lower versus the last price from Nov 3, 2026 of $0.0500 (overvalued). The calculation is refreshed regularly with new filings.
What is the revenue of Vycor Medical Inc (VYCO)?
Vycor Medical Inc reported trailing-twelve-month revenue of about $1.8M (latest available figure, as of Nov 7, 2026).
What is the intrinsic value of Vycor Medical Inc (VYCO)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Vycor Medical Inc it is $0.0300 per share (as of Nov 7, 2026), against a price of $0.0500. It is the blended result of 3 valuation models in 3 families (Earnings-Based, Multiples, Economic Profit).
Is Vycor Medical Inc stock overvalued or undervalued in 2026?
As of Nov 7, 2026, VYCO trades above its calculated fair value: price $0.0500, fair value $0.0300, a gap of about −40% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of VYCO?
No. The price is what the market pays today ($0.0500); the fair value is what the company's own numbers justify ($0.0300). For Vycor Medical Inc the two are $0.0200 per share apart. That gap is exactly why we show both numbers side by side.
How much is Vycor Medical Inc worth?
The market values Vycor Medical Inc at about $1.7M (market capitalisation, as of Nov 7, 2026). Per share that is $0.0500; our models calculate a fair value of $0.0300 per share.
How solid is the balance sheet of Vycor Medical Inc (VYCO)?
Balance-sheet figures for Vycor Medical Inc (as of Nov 7, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 47/100, which measures business quality independently of the share price.
How far is VYCO from its 52-week high?
Vycor Medical Inc trades at $0.0500, about 75% below its 52-week high of $0.2000 and 92% above the low of $0.0260 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0300 is for.
Which stocks are comparable to Vycor Medical Inc?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Vycor Medical Inc stock attractive at the current price?
The data as of Nov 7, 2026: price $0.0500, calculated fair value $0.0300 (−40%), Quality Score 47/100, from 3 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of VYCO calculated?
We run Vycor Medical Inc through 3 models from 3 families: Earnings-Based, Multiples, Economic Profit. Every model gets the same audited fundamentals; the fair value of $0.0300 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.7% above its aggregate fair value. Vycor Medical Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Vycor Medical Inc (VYCO)?
The latest price we hold is from Nov 3, 2026 and stands at $0.0500. Our model-based fair value is $0.0300, about 40% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Vycor Medical Inc right now?
The price sits above even our optimistic bull case ($0.0300). The favourable scenario is already priced in. Weak quality (47/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Vycor Medical Inc

How large is the market capitalisation of Vycor Medical Inc (VYCO)?
The market capitalisation of Vycor Medical Inc is $1.7M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Vycor Medical Inc (VYCO)?
The price-to-sales ratio of Vycor Medical Inc is 0.96 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Vycor Medical Inc (VYCO)?
The net margin of Vycor Medical Inc is −3.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the EBIT return on assets of Vycor Medical Inc (VYCO)?
On an EBIT basis the return on assets of Vycor Medical Inc is −15.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Vycor Medical Inc (VYCO)?
The operating margin of Vycor Medical Inc is 1.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Vycor Medical Inc (VYCO)?
Revenue at Vycor Medical Inc is growing −15.7% versus a year earlier (3y avg +15.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Vycor Medical Inc (VYCO) generate?
The free cash flow of Vycor Medical Inc is −$18.7K (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Vycor Medical Inc (VYCO) carry?
The net debt of Vycor Medical Inc is $869K (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Vycor Medical Inc in the live analysis

One click puts Vycor Medical Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.